Bioasis Technologies

Bioasis Technologies P/B

The P/B (Price-to-Book Ratio) of Bioasis Technologies (BIOAF) as of Oct 24, 2026 is -0.01. In the previous year, P/B (Price-to-Book Ratio) was 0.03 — a change of -121.24% (lower).

P/B

-0.01

YoY

-121.24%

Last updated:

P/B (Price-to-Book Ratio) of Bioasis Technologies is 2022 -0.01 . P/B (Price-to-Book Ratio) of Bioasis Technologies was 2021 0.03 . It decreases by -121.24% lower compared to the previous year.

The Bioasis Technologies P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2015
0.01 CAD
Jan 1, 2016
0.01 CAD
Jan 1, 2017
0.04 CAD
Jan 1, 2018
0.03 CAD
Jan 1, 2019
-0.02 CAD
Jan 1, 2020
-0.01 CAD
Jan 1, 2021
0.03 CAD
Jan 1, 2022
-0.01 CAD
The Bioasis Technologies P/B history
YEARP/BYoY
-0.01-121.24%
0.03-710.59%
-0.01-78.01%
-0.02-179.42%
0.03-16.29%
0.04+373.09%
0.01+16.63%
0.01+19.24%
0.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioasis Technologies Stock analysis

What does Bioasis Technologies do? biOasis Technologies, Inc. generates revenue by developing therapeutics using its proprietary xB3 platform, which is designed to deliver treatments across the blood brain barrier for central nervous system disorders. The company focuses on areas of high unmet medical need, specifically targeting brain cancers and neurodegenerative diseases. This technology leverages a human transport protein found circulating at low levels in the blood to shuttle molecules to their targets within the brain via receptor-mediated transcytosis. The firm markets its in-house development programs aimed at creating both symptomatic and disease-modifying treatments for brain-related diseases and disorders. By utilizing the xB3 platform, biOasis Technologies, Inc. addresses specific therapeutic challenges in the central nervous system, offering solutions for conditions that currently lack adequate medical interventions. The business model relies on the efficacy of this delivery system to reach targets within the brain, serving the needs of patients suffering from these severe neurological conditions. Bioasis Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioasis Technologies stock

P/B (Price-to-Book Ratio) of Bioasis Technologies is -0.01 in 2022.

P/B (Price-to-Book Ratio) of Bioasis Technologies changed from 0.03 to -0.01, representing a -121.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Bioasis Technologies since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Bioasis Technologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Bioasis Technologies

All Key Metrics — Bioasis Technologies